Pluri (PLUR) Other financing activities (2011 - 2020)

Pluri (PLUR) posted quarterly Other financing activities of $64000.0 for Q4 2020, down 78.67% quarter-over-quarter from $300000.0 in Q3 2020.

Pluri (PLUR) Other financing activities (2011 - 2020) Analysis & Trends

Pluri (PLUR) has reported Other financing activities for 10 consecutive years, with $64000.0 the latest figure, recorded in Q4 2020.

In Q4 2020, Other financing activities changed N/A year-over-year to $64000.0; the TTM figure through Jun 2021 stood at $364000.0 (changed N/A YoY), while the FY2025 annual figure was -$47000.0, down 100.54% from the prior year.
Other financing activities declined to $64000.0 in Q4 2020 per PLUR's latest filing, from $300000.0 in the prior quarter.
Across five years, Other financing activities topped out at $1.1 million in Q2 2018 and bottomed at -$99000.0 in Q4 2018.
Historically, Other financing activities has averaged $126461.5 across 5 years, with a median of $59000.0 in 2017.
On a YoY basis, Other financing activities climbed as much as 1788.14% in 2018 and fell as far as 254.69% in 2018.
Pluri's Other financing activities stood at $4000.0 in 2016, then jumped by 1500.0% to $64000.0 in 2017, then slumped by 254.69% to -$99000.0 in 2018, then changed by 0.0% to -$99000.0 in 2019, then surged by 164.65% to $64000.0 in 2020.
Business Quant data shows PLUR's Other financing activities at $64000.0 in Q4 2020, $300000.0 in Q3 2020, and -$99000.0 in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Pluri	16.21 Mn	3.72 Mn	86,000.00

Download Data